CS 014
Alternative Names: CS-014; EB-014Latest Information Update: 25 Apr 2025
At a glance
- Originator Emeriti Bio
- Developer Cereno Scientific; Emeriti Bio
- Class Antifibrotics; Antithrombotics; Cardiovascular therapies; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
- Discontinued Cardiovascular disorders; Thrombosis
Most Recent Events
- 25 Apr 2025 Discontinued - Phase-I for Cardiovascular disorders in Sweden (unspecified route)
- 25 Apr 2025 Discontinued - Phase-I for Thrombosis (Prevention) in Sweden (unspecified route)
- 25 Apr 2025 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in Sweden (unspecified route) (Cereno Scientific pipeline, April 2025)